Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 171.79%. A quarter ago, it was expected that this drugmaker would post earnings of $0.37 per share when it actually produced earnings of $0.36, delivering a surprise of -2.70%.Over the last four quarters, the ...

Core Insights - Supernus Pharmaceuticals presented new data on SPN-820, a novel treatment for major depressive disorder (MDD), at Psych Congress 2024, highlighting its rapid onset and favorable safety profile [1][5][6] Study Results - The Phase 2a study involved 40 subjects with MDD, assessing the efficacy and safety of SPN-820 administered at 2400 mg every three days [7] - Participants showed significant reductions in depressive symptoms, with a decrease of 80% in suicidal ideation from 12.5% at baseline to 2.6% by Day 10 [4] - The Hamilton Depression Rating Scale-6 items (HAM-D6) showed improvements of -6.1 at two hours and -9.6 at Day 10, while the Montgomery Åsberg Depression Rating Scale (MADRS) indicated improvements of -16.6 at four hours and -22.9 at Day 10 [2] Efficacy and Tolerability - Rapid response rates were observed, with 50% of participants achieving a ≥50% reduction in MADRS scores at four hours, increasing to 84.2% by Day 10 [3] - The tolerability profile was favorable, with a low discontinuation rate of 2.5% due to adverse events, which were mostly mild to moderate [4][5] Mechanism of Action - SPN-820 is a first-in-class, orally active small molecule that modulates the mTORC1 pathway, enhancing synaptic function and cellular metabolism in the brain [6] - The compound is designed to provide rapid antidepressant effects without dissociative side effects, with ongoing Phase 2b studies involving approximately 227 patients with treatment-resistant depression [6]

ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to pre ...

Core Insights - Supernus Pharmaceuticals announced positive results from its Phase 2a clinical study of SPN-820, a novel treatment for major depressive disorder, demonstrating a rapid and substantial decrease in depressive symptoms [1][3] - The company plans to host a webcast to discuss the topline data and expects to release results from a Phase 2b study in the first half of 2025 [1][3] Study Results - The Phase 2a study involved 40 subjects, with 38 completing the treatment, showing a clinically meaningful improvement of -6.1 at two hours and -9.6 at Day 10 on the Hamilton Depression Rating Scale-6 Items (HAM-D6) [2][6] - On the Montgomery Åsberg Depression Rating Scale (MADRS), improvements of -16.6 at four hours and -22.9 at Day 10 were observed [2] - Suicidal ideation decreased by 80%, from 12.5% at baseline to 2.6% at Day 10 [2] Safety and Tolerability - SPN-820 was well-tolerated, with a low discontinuation rate of 2.5% due to adverse events [2] - Common adverse events included headache, nausea, somnolence, and dizziness, with additional events such as cognitive disorder and dry mouth reported [2] Product Overview - SPN-820 is a first-in-class, orally active small molecule that enhances synaptic function via mTORC1 modulation, aiming for rapid antidepressant effects without dissociative side effects [5] - The ongoing Phase 2b study will involve approximately 227 adult patients with treatment-resistant depression [5]

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder. A live webcast with presentation slides will be ...

Core Insights - The article highlights the importance of raising awareness about ADHD, particularly in women, and emphasizes the role of Qelbree as a treatment option for managing ADHD symptoms [1][2][3] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases, including ADHD [11] - The company is committed to providing treatment options and education for individuals living with ADHD, as stated by its CEO, Jack A. Khattar [4] Product Information - Qelbree (viloxazine extended-release capsules) is a non-stimulant medication approved for the treatment of ADHD in patients aged 6 years and older, marking the first non-stimulant approved for adults in 20 years [3][5] - Qelbree is designed to be taken once daily and has no evidence of abuse or misuse, allowing for convenient refills without the need for a new prescription each month [3] Market Context - Approximately 10 million adults in the U.S. live with ADHD, and the article emphasizes the challenges they face in managing their symptoms, particularly during transitions like the start of the school year [2] - The article aims to empower individuals, especially women, to seek treatment options and advocate for their health [2][3]

Simon Webb and Duncan Nicholls/OJO Images via Getty Images Investment Overview The last - and also the first - time I covered Supernus Pharmaceuticals (NASDAQ:SUPN) for Seeking Alpha was in November 2023. I gave the company's stock a "strong buy" rating - shares traded at $26 at the time - and at the time of writing they trade at a value of $30 - up ~15%. I own some stock in the company myself. At the end of last week, shares actually traded at $35 per share - up 35% since my note - however the market has b ...

Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected. "That has us rethinking our assumptions regarding the longer-term (LT) sales/volume growth trajectory of the product," the analyst adds. Qelbree (viloxazine) is indicated to treat attention deficit hyperactivity disorder in children and adults. In the second quarter of 2024, net sales of Qelbree increased 92% year over year ...

ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts. Investo ...

Supernus Pharmaceuticals (SUPN) closed the last trading session at $31.48, gaining 10.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $40.50 indicates a 28.7% upside potential. The average comprises four short-term price targets ranging from a low of $38 to a high of $43, with a standard deviation of $2.08. While the lowest estimate indicates an increase of 20.7% from the curren ...